Adial Pharmaceuticals, Inc (ADIL) News

Adial Pharmaceuticals, Inc (ADIL): $0.39

-0.01 (-2.23%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Filter ADIL News Items

ADIL News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

ADIL News Highlights

  • ADIL's 30 day story count now stands at 2.
  • Over the past 23 days, the trend for ADIL's stories per day has been choppy and unclear. It has oscillated between 1 and 1.

Latest ADIL News From Around the Web

Below are the latest news stories about ADIAL PHARMACEUTICALS INC that investors may wish to consider to help them evaluate ADIL as an investment opportunity.

Adial Pharmaceuticals Enters Into Option Agreement for Sale of Purnovate Assets to Adenomed

Adial to focus on late-stage clinical development for AD04 for alcohol use disorder; potential sale of Purnovate to new company formed by former Adial CEO and current Purnovate CEO, William Stilley Potential development/commercial milestone payments of up to $83 million on first three compounds plus equity stake and ongoing royalties CHARLOTTESVILLE, Va., Feb. 01, 2023 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”) a clinical-stage biopharmaceuti

Yahoo | February 1, 2023

Was anything positive for Adial Pharmaceuticals Inc. (ADIL) stock last session?

A share of Adial Pharmaceuticals Inc. (NASDAQ:ADIL) closed at $0.35 per share on Friday, up from $0.25 day before. While Adial Pharmaceuticals Inc. has overperformed by 37.29%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, ADIL fell by -86.00%, with highs and lows ranging from $2.80 […]

US Post News | January 9, 2023

Adial Pharmaceuticals, Inc. (ADIL) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?

Adial Pharmaceuticals, Inc. (ADIL) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.

Yahoo | December 1, 2022

Maxim Group Reaffirms Their Hold Rating on Adial Pharmaceuticals (ADIL)

In a report released yesterday, Jason McCarthy from Maxim Group maintained a Hold rating on Adial Pharmaceuticals (ADIL - Research Report). The company's shares opened today at $0.29.McCarthy covers the Healthcare sector, focusing on stocks such as Immutep, Daré Bioscience, and Adial Pharmaceuticals. According to TipRanks, McCarthy has an average return of -38.1% and a 14.47% success rate on recommended stocks. The analyst consensus on Adial Pharmaceuticals is currently a Hold rating.See the top stocks recommended by analysts >>The company has a one-year high of $3.52 and a one-year low of $0.24. Currently, Adial Pharmaceuticals has an average volume of 166K.

Catie Powers on TipRanks | November 15, 2022

Adial Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Business Update

Advancing submission of AD04 ONWARD™ phase 3 results to regulatory agencies Actively exploring potential partnership opportunities for AD04 and Purnovate compounds

GlobeNewswire | November 14, 2022

Adial Pharmaceuticals, Inc: Adial Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Business Update

Advancing submission of AD04 ONWARD™ phase 3 results to regulatory agencies Actively exploring potential partnership opportunities for AD04 and Purnovate compounds Promoted Cary Claiborne to Presi…

Finanz Nachrichten | November 14, 2022

Forget Bargain Hunting: Play 5 Stocks With Rising P/E

Bet on these top-ranked stocks with rising P/E to realize outsized gains. Tap Eastside Distilling (EAST), Adial Pharmaceuticals (ADIL), The Buckle (BKE), Ruth's Hospitality Group (RUTH), Insight Enterprises (NSIT).

Yahoo | October 19, 2022

Maxim Group Sticks to Its Hold Rating for Adial Pharmaceuticals (ADIL)

Maxim Group analyst Jason McCarthy maintained a Hold rating on Adial Pharmaceuticals (ADIL - Research Report) yesterday. The company's shares opened today at $0.42.According to TipRanks, McCarthy is an analyst with an average return of -44.0% and an 8.84% success rate. McCarthy covers the Healthcare sector, focusing on stocks such as Adial Pharmaceuticals, Atossa Therapeutics, and Capricor Therapeutics.Adial Pharmaceuticals has an analyst consensus of Moderate Buy.See Insiders’ Hot Stocks on TipRanks >> The company has a one-year high of $5.00 and a one-year low of $0.34. Currently, Adial Pharmaceuticals has an average volume of 737.3K.

Carrie Williams on TipRanks | September 27, 2022

Adial Pharma Touts Positive Preclinical Data From Chronic Pain Candidate

Adial Pharmaceuticals Inc''s (NASDAQ: ADIL ) subsidiary, Purnovate Inc, achieved positive in vivo data for PNV-5030 as a potential treatment for chronic pain. The study was conducted in four groups of ten rats that underwent surgical injury of the sciatic nerve. At 30 minutes post-dose, PNV-5030 reduced pain by 43% compared to the control group, while acetaminophen (APAP) doses did not … Full story available on Benzinga.com

Benzinga | September 26, 2022

Adial Pharmaceuticals Announces Positive In Vivo Data for Purnovate’s PNV-5030 as a Potential Treatment for Chronic Pain

PNV-5030 significantly reduced pain compared to both placebo and acetaminophen PNV-5030 significantly reduced pain compared to both placebo and acetaminophen

GlobeNewswire | September 26, 2022


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.4967 seconds.